Hubert C. Chen - Apr 1, 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role
President and Chief Scientific Officer
Signature
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol
FBRX
Transactions as of
Apr 1, 2023
Transactions value $
-$2,619
Form type
4
Date filed
4/4/2023, 08:17 PM
Previous filing
Feb 27, 2023
Next filing
Jul 5, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FBRX Common Stock Options Exercise $0 +7.5K $0.00 7.5K Apr 1, 2023 Direct F1
transaction FBRX Common Stock Tax liability -$2.62K -2.59K -34.57% $1.01 4.91K Apr 1, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FBRX Restricted Stock Units Options Exercise $0 -7.5K -6.25% $0.00 113K Apr 1, 2023 Common Stock 7.5K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F2 On April 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on March 31, 2023 was the settlement price used to calculate the shares withheld.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Remarks:

President and Chief Scientific Officer